At Work With: John Curbishley

John Curbishley
John Curbishley
JOHN CURBISHLEY
EVP, Business and Product ­Development, AccentHealth

What was your biggest break?
Being admitted to Oxford University—it gave me an entirely new perspective on what I could achieve.

What's the best and/or worst part of your job?
Meeting new digital companies and figuring out creative ways to work with them.

What's the view like from your office/work area?
I have a great New York City view—a backdrop of skyscrapers with an old wooden water tower in the foreground.

Does your office have a favorite lunch and/or after-hours place?
The team here is very social but there's no one spot—we are by Grand Central so there are a lot of places nearby.

What was your greatest professional challenge?
At NBC I negotiated licensing deals in many countries with different cultures and paces of doing business.

Where will you be in five years?
I just joined the team here at AccentHealth so hope I will still be here.

If you were to write a book, what would the title be?
Legal Alien—Tales of an Englishman in Corporate America
You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.